Patient Education in Children With Functional Gastrointestinal Disorders

Sponsor
Karolinska Institutet (Other)
Overall Status
Completed
CT.gov ID
NCT04294420
Collaborator
(none)
25
1
1
19
1.3

Study Details

Study Description

Brief Summary

This pilot-study aims to evaluate the effect size and feasibility of patient education for children and adolescents (age 8-17 years) with pain-predominant functional gastrointestinal disorders (irritable bowel syndrome, functional abdominal pain and functional dyspepsia according to the Rome III criteria).

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Patient education program
N/A

Detailed Description

The patient education will be provided in a group setting and the children will participate along with one of their parents. Education consists of 2-hour long group sessions, given at 2 different occasions within a month.

The hypothesis is that patient education will reduce gastrointestinal symptoms and pain and also improve quality of life in this group of patients.

Study Design

Study Type:
Interventional
Actual Enrollment :
25 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Patient Education in Children and Adolescents With Pain-predominant Functional Gastrointestinal Disorders: a Pilot Study
Actual Study Start Date :
May 1, 2020
Actual Primary Completion Date :
May 1, 2021
Actual Study Completion Date :
Dec 1, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: Patient education program

Patient education program

Behavioral: Patient education program
The education program provides information and guidance concerning aetiology, diagnostics and treatment of pain-predominant functional gastrointestinal disorders. The patient education program will be provided in a group setting and the children will participate along with one of their parents. The participants (n=20) will be divided into two groups consisting of ten child-parent pairs. Two lectures will be held, two weeks apart, two hours per lecture. Represented teachers are physician, psychologist and dietician.

Outcome Measures

Primary Outcome Measures

  1. Treatment acceptability [Baseline to 3 months.]

    A questionnaire to child /adolescent if they found the education logic. If they believe it will decrease symptoms. If they would recommend it to others

Secondary Outcome Measures

  1. Pediatric Quality of Life Inventory Gastrointestinal Symptoms Scales (PedsQL Gastro) [Baseline to 3 months, baseline to 6 months.]

    Change in gastrointestinal symptoms measured with with a 14-item scale ranging from 0 (never) to 4 (almost always) measured from baseline to three months and from baseline to six months for analysis of effect. Improvements yield increased values.

  2. Rome IV Diagnostic Questionnaire on Pediatric Functional Gastrointestinal Disorders (R4PDQ) [Baseline to 3 months, baseline to 6 months.]

    Change in children's functional gastrointestinal disorders diagnostic status measured by Rome IV Diagnostic Questionnaire on Pediatric Functional Gastrointestinal Disorders (R4PDQ) - Child: Non-numerical self-report form for Children and Adolescents (10 years and older) measured from baseline to three months and from baseline to six months for analysis of effect as a self-rating scale from baseline to three months and from baseline to six months for analysis of effect.

  3. Faces Pain Rating Scale. (FACES) [Baseline to 3 months, baseline to 6 months.]

    Change in pain intensity measured with a self-rating scale daily during two weeks at baseline, daily during two weeks after 3 months and daily during two weeks after 6 months for analysis of effect. The Faces Pain Scale is a self-report measure used to assess the intensity of children's pain. Faces have four faces representing least pain and most pain on equal intervals on a scale from 0 (no pain)-10 (worst pain). Its validity is supported by a strong positive correlation (r=0.93, N=76) with a visual analogue scale (VAS) measure in children aged 5-12 years. The metric for scoring (0-10) conforms closely to a linear interval scale.Higher scores indicates higher levels of pain.

  4. Pediatric Quality of Life Inventory (PedsQL) [Baseline to 3 months, baseline to 6 months.]

    Change in quality of life from baseline to three months and from baseline to six months measured with a self-report scale that measures quality of life in adolescents. PedsQL Generic Core scales is a 23-item scale ranging from 0 (never) to 4 (almost always). Improvements yield increased values. The PedsQL is shown to distinguish between healthy children and adolescents and pediatric patients with acute or chronic health conditions and demonstrate acceptable reliability and validity.

  5. The behavioral responses questionnaire child-adapted short scale (BRQ-C) [Baseline to 3 months, baseline to 6 months.]

    Change in Gastrointestinal symptom-specific behaviors measured with a self-rating scale from baseline to three months and from baseline to 6 months, for analysis of effect. The BRQ-C comprise 11 items on a 7 point-scale, with only endpoints defined: never (0) and always (7). Higher scores indicates higher levels of gastrointestinal symptoms.

  6. Children's Somatization Inventory (CSI-24) - subscale for gastrointestinal symptoms (CSI gastro) [Baseline to 3 months, baseline to 6 months.]

    A questionnaire that assesses the perceived severity of 24 nonspecific somatic symptoms. Items are based off of the symptom criteria for somatization disorders as defined by the Diagnostic and Statistical Manual of Mental Disorders (DSM). We will use the subscale for gastrointestinal symptoms (CSI gastro) with questions concerning presence of gastrointestinal symptoms measured with a 7-item scale ranging from 0 (not at all) to 4 (very much) measured from baseline to three months and from baseline to six months. Higher scores indicates higher levels of somatization.

  7. Spence Children Anxiety Scale - short version (SCAS-S) [Baseline to 3 months, baseline to 6 months.]

    The SCAS-S assesses anxiety in children. The frequency of anxiety symptoms is rated on a 4-point scale, with answers ranging from never (0) to always (3). Higher scores indicates higher levels of anxiety. The SCAS-S will be assessed from baseline to three months and from baseline to six months.

  8. Child Depression Inventory - short version (CDI-S) [Baseline to 3 months, baseline to 6 months.]

    Child Depression Inventory (CDI) is a self-measure of child depression symptoms. The short version of the CDI (CDI-S) consists of 10 items graded from 0 (no symptoms) to 2 (severe symptoms). The questionnaire covers depressive symptoms such as self-blame, loss of appetite and insomnia. The CDI-S has shown high correlation to other measures of depression and should be considered a valid measure of depression symptoms. Symptoms measured from baseline to three months and from baseline to six months. Higher scores indicates higher levels of depression.

Eligibility Criteria

Criteria

Ages Eligible for Study:
8 Years to 17 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Children and adolescents between 8-17 years (until their 18th birthday) who have been diagnosed with any of the diagnoses irritable bowel syndrome, functional dyspepsia or functional abdominal pain according to the Rome III criteria.

  • Blood samples, with normal outcome, in terms of complete blood count (CBC), Erythrocyte Sedimentation Rate (ESR), Anti-tissue Transglutaminase Antibody (tTG), and dipstick urinalysis. Faecal Calprotectin should be measured if diarrhea is present.

Exclusion Criteria:
  • Insufficient skills in the Swedish language.

  • Severe psychiatric comorbidity (as suicidality, psychosis etc).

  • Severe somatic comorbidity.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Karolinka Institutet Stockholm Sweden 17177

Sponsors and Collaborators

  • Karolinska Institutet

Investigators

  • Principal Investigator: Agneta Uusijärvi, MD PhD, Karolinska Institute, CLINTEC

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Agneta Uusijärvi, Principal Investigator, Karolinska Institutet
ClinicalTrials.gov Identifier:
NCT04294420
Other Study ID Numbers:
  • 2019-05417
First Posted:
Mar 4, 2020
Last Update Posted:
Dec 17, 2021
Last Verified:
Dec 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 17, 2021